What it sells
Modernises chemical production.
Business model breakdown
Buyer: who owns the budget?
Process development / R&D leaders at pharmaceutical, agrochemical and specialty chemical companies (e.g. AstraZeneca retrospective case).
Trigger: what makes them buy now?
One reaction holding up a programme, or a need for solvent replacement and scale-up kinetics faster than months of lab work.
Workflow: what inputs become what output?
Runs reactions in an automated lab, delivers FAIR data via download or API, and fits kinetic models to scale up right first time.
Economics: what it saves and how it charges
Sells data and insights; claims data in days vs months and kinetic modeling over 50x faster.
Distribution: how it reaches customers
'Get in touch' contact-led; case studies.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-01-28 | — | £4M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.